Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), ...

We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Tempus enters earnings with strong tailwinds but ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...